poisar

Stocks · News reference

BTIG Maintains Buy Rating and $29 Price Target for ArriVent BioPharma

Fiscal.ai

BTIG analyst Jeet Mukherjee has reiterated a Buy rating and a $29.00 price target on ArriVent BioPharma, Inc.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading